ArticleFrontiers in cardiovascular medicine2026
The HEART score has less utility with high sensitivity troponin.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clinical risk scores for acute chest pain evaluation were largely validated using older troponin assays. We sought to analyze the HEART score and clinical decision pathways utilizing high sensitivity troponin. Methods: This was a retrospective study of all adult patients presenting with nontraumatic chest pain to a single center, quaternary-care emergency department over a 6-month time period. Patients were risk-stratified by the HEART score using an institution-specific clinical decision pathway that aligns with current guidelines. Predictive models and optimal cutoff values were constructed via logistic regression for the primary outcome of acute coronary syndrome at presentation or major adverse cardiovascular events within 30 days and additional analysis was performed among risk groups assessing associations of HEART score with negative troponin and electrocardiogram compared to positive troponin or electrocardiogram. Results: Data from 1,014 patients were included for analysis with 46 patients (4.5%) meeting the primary outcome. The model most associated with the primary outcome utilized electrocardiogram and high-sensitivity troponin only (C-statistic = 0.883), which reliably predicted the absence of the primary outcome in intermediate risk patients. The addition of medical history, risk factors, and age to this model (via the continuous HEART score) did not increase its value (C-Statistic 0.876). Conclusion: Our study suggests that high-sensitivity troponin and electrocardiogram alone can be used to risk stratify most patients with acute chest pain appropriately. Traditional scoring systems developed with contemporary cardiac troponin assays have less utility in the era of high sensitivity troponin, especially with patients previously deemed intermediate risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.